

### **Novartis Egypt launches 1st-of-its-kind migraine preventative drug in Egyptian market**

Novartis Pharma organized a press conference to unveil Erenumab, a leading treatment for migraine prevention. Migraine affects more than 10% of the global population and is two to three times more common in women than men. The disease is most common between the ages of 25 and 55. Clinical studies have shown that Erenumab reduces monthly migraine attacks by 75%, helping patients to carry out daily activities normally with almost no side effects.